Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilding, J.
Right arrow Articles by Ilyas, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilding, J.
Right arrow Articles by Ilyas, M.
[Cancer Research 62, 4562-4565, August 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Cyclin D1 Is Not an Essential Target of ß-Catenin Signaling During Intestinal Tumorigenesis, but It May Act as a Modifier of Disease Severity in Multiple Intestinal Neoplasia (Min) Mice1

Jenny Wilding, Josef Straub, Julie Bee, Michael Churchman, Walter Bodmer, Clive Dickson, Ian Tomlinson and Mohammad Ilyas2

Cancer and Immunogenetics Laboratory, Cancer Research UK, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom [J. W., W. B.]; Bayer AG, D-42096 Wuppertal, Germany [J. S.]; Biological Resources [J. B.], Viral Carcinogenesis Laboratory [C. D.], and Molecular and Population Genetics Laboratory [I. T.], Cancer Research UK, London WC2A 3PX, United Kingdom; and Oxford Molecular Pathology Group, Level 3, The Women’s Centre, John Radcliffe Hospital, Headington, Oxford OX3 9DU, United Kingdom [M. C., M. I.]

Deregulation of ß-catenin activity is an important step in the development of colorectal cancers. One consequence of this is transcriptional activation of cyclin D1, an oncogene known to be overexpressed in colorectal cancers. We tested the hypothesis that cyclin D1 gene activation is important for intestinal tumorigenesis. Multiple intestinal neoplasia mice (a model for human familial adenomatous polyposis) were crossed with cyclin D1 knockout (Ccnd1-/-) mice. Despite the absence of cyclin D1, intestinal tumors still developed. However, Ccnd1-/- multiple intestinal neoplasia mice developed significantly fewer tumors than Ccnd1+/- or Ccnd1+/+ mice (P = 0.003). We conclude that cyclin D1 is not essential for intestinal tumorigenesis, but it may act as a modifier gene.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
U. Dougherty, A. Sehdev, S. Cerda, R. Mustafi, N. Little, W. Yuan, S. Jagadeeswaran, A. Chumsangsri, J. Delgado, M. Tretiakova, et al.
Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model
Clin. Cancer Res., April 15, 2008; 14(8): 2253 - 2262.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J. Schneikert and J. Behrens
The canonical Wnt signalling pathway and its APC partner in colon cancer development
Gut, March 1, 2007; 56(3): 417 - 425.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. J. Sansom, K. R. Reed, M. van de Wetering, V. Muncan, D. J. Winton, H. Clevers, and A. R. Clarke
Cyclin D1 Is Not an Immediate Target of {beta}-Catenin following Apc Loss in the Intestine
J. Biol. Chem., August 5, 2005; 280(31): 28463 - 28467.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. M. Sieber, K. M. Howarth, C. Thirlwell, A. Rowan, N. Mandir, R. A. Goodlad, A. Gilkar, B. Spencer-Dene, G. Stamp, V. Johnson, et al.
Myh Deficiency Enhances Intestinal Tumorigenesis in Multiple Intestinal Neoplasia (ApcMin/+) Mice
Cancer Res., December 15, 2004; 64(24): 8876 - 8881.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M D Crabtree, C Fletcher, M Churchman, S V Hodgson, K Neale, R K S Phillips, and I P M Tomlinson
Analysis of candidate modifier loci for the severity of colonic familial adenomatous polyposis, with evidence for the importance of the N-acetyl transferases
Gut, February 1, 2004; 53(2): 271 - 276.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. C. Faux, J. L. Ross, C. Meeker, T. Johns, H. Ji, R. J. Simpson, M. J. Layton, and A. W. Burgess
Restoration of full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion
J. Cell Sci., January 22, 2004; 117(3): 427 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. M. Rowlands, I. V. Pechenkina, S. J. Hatsell, R. G. Pestell, and P. Cowin
Dissecting the roles of {beta}-catenin and cyclin D1 during mammary development and neoplasia
PNAS, September 30, 2003; 100(20): 11400 - 11405.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Yamada, Y. Mori, R. Hayashi, M. Takada, Y. Ino, Y. Naishiro, T. Kondo, and S. Hirohashi
Suppression of Intestinal Polyposis in Mdr1-deficient ApcMin/+ Mice
Cancer Res., March 1, 2003; 63(5): 895 - 901.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.